Cost of Revenue Comparison: Gilead Sciences, Inc. vs Mesoblast Limited

Cost of Revenue: A Tale of Two Companies

In the ever-evolving landscape of biotechnology, Gilead Sciences, Inc. and Mesoblast Limited stand as intriguing case studies. From 2014 to 2023, Gilead Sciences consistently reported a cost of revenue that dwarfed Mesoblast's, with figures peaking at approximately $6.6 billion in 2021. This represents a staggering 1,200% increase compared to Mesoblast's highest cost of revenue, which reached around $85.7 million the same year.

Gilead's cost of revenue saw a notable rise of about 72% from 2014 to 2023, reflecting its expansive operations and market reach. In contrast, Mesoblast's cost of revenue fluctuated, peaking in 2021 before declining. The data for 2024 is incomplete, highlighting the dynamic nature of financial reporting. This comparison underscores the diverse strategies and market positions of these two biotech firms, offering valuable insights into their operational scales and financial health.